BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berkel C, Cacan E. Estrogen- and estrogen receptor (ER)-mediated cisplatin chemoresistance in cancer. Life Sci 2021;286:120029. [PMID: 34634322 DOI: 10.1016/j.lfs.2021.120029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Azmi AS, Mohammad RM. Deregulated transcription factors and poor clinical outcomes in cancer patients. Semin Cancer Biol 2022;86:122-34. [PMID: 35940398 DOI: 10.1016/j.semcancer.2022.08.001] [Reference Citation Analysis]
2 Chiang C, Yang H, Zhu L, Chen C, Chen C, Zuo Y, Zheng D. The Epigenetic Regulation of Nonhistone Proteins by SETD7: New Targets in Cancer. Front Genet 2022;13:918509. [DOI: 10.3389/fgene.2022.918509] [Reference Citation Analysis]
3 Alemohammad H, Motafakkerazad R, Asadzadeh Z, Farsad N, Hemmat N, Najafzadeh B, Vasefifar P, Baradaran B. siRNA-mediated silencing of Nanog reduces stemness properties and increases the sensitivity of HepG2 cells to cisplatin. Gene 2022;821:146333. [PMID: 35182674 DOI: 10.1016/j.gene.2022.146333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yoon J, Kim H, Jeong YI, Yang HS. CD44 Receptor-Mediated/Reactive Oxygen Species-Sensitive Delivery of Nanophotosensitizers against Cervical Cancer Cells. Int J Mol Sci 2022;23:3594. [PMID: 35408970 DOI: 10.3390/ijms23073594] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]